• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Thailand·Consumer Cyclical·BIS.BK
Share

Bioscience Animal Health Public Company Limited Stocks

THB 2.74Last Updated 18.09.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

THB 27.55M

THB 2.74
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Nonthaburi, Thailand, Bio Science Animal Health Public Company Limited (BIS.BK) is a Thai firm engaged in the distribution of animal pharmaceuticals, feed additives, and raw materials. It serves the livestock, aquaculture, and pet sectors across Thailand. The company's comprehensive product range includes bioscience offerings such as antibiotics, various additives, injectable solutions, mold inhibitors, water-soluble formulations, and vaccines. Furthermore, it provides feed additives, disinfectants, amino acids, essential medical supplies, diagnostic instruments, and a full line of animal health and nutrition products. This enterprise was founded in 2004.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.09.2026 21:00

Anthropic Has Chosen a Stock Exchange; OpenAI Is Aiming for $1.2 Trillion: Key Takeaways on IPOs by September 20

20.09.2026 15:01

Does having a lot of money make an investor more rational? Yes, but only to a certain extent

19.09.2026 16:01

Small-Cap Highlights: Management Shuffle at Hugo Boss, LSD's Success, Yoox Outlet's Surge

19.09.2026 13:01

AI: To Accelerate or Slow Down? Revolut Takes on Extortionists; Luxury Is Becoming More Affordable

19.09.2026 03:54

Trump signed a law imposing sanctions on Russia. It will affect major oil importers.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026